Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00971191 · ClinicalTrials.gov registry record · Phase 1

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

A Phase 1 study, sponsored by Pfizer.

Terminated
Registry status
Phase 1
Development phase
22
Enrollment target

NCT00971191: Clinical Trial Phase 1 study, sponsored by Pfizer.

NCT00971191 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00971191, a Phase 1 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.

Interventions

  • DRUG PF-00299804

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2010-02
Est. Completion 2012-05
Phase Phase 1
Pfizer

1,845 total trials

Why NCT00971191 stopped before completion

NCT00971191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 1 intervention - of which PF-00299804 is the first listed.

NCT00971191 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00971191 about?

NCT00971191 is a clinical study titled "A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804". This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.

What is the current status of trial NCT00971191?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-02. Estimated completion is 2012-05.

What interventions are being tested in trial NCT00971191?

The interventions under investigation include: PF-00299804 (DRUG).

Who is sponsoring clinical trial NCT00971191?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00971191's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00971191, the US trial registry maintained by the National Library of Medicine. NCT00971191 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.